Tissue renin-angiotensin systems: A unifying hypothesis of metabolic disease

Frontiers in Endocrinology

Volumn 5, Issue FEB, 2014, Pages

  Skov, Jeppe ^a,b   Persson, Frederik ^c   Frøkiær, Jørgen ^a,d   Christiansen, Jens Sandahl ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c STENO DIABETES CENTER   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

Cortisol; Diabetes; GLP 1; Metabolic syndrome; Obesity; Osteoporosis; Renin angiotensin system; Vitamin D

Indexed keywords

ANGIOTENSIN II; AQUAPORIN 2; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOCORTICOID; HYDROCORTISONE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; REACTIVE OXYGEN METABOLITE; VALSARTAN; VASOPRESSIN; VITAMIN D;

AEROBIC EXERCISE; ARTICLE; BONE REMODELING; CELL PROLIFERATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; METABOLIC DISORDER; NONHUMAN; OBESITY; PREGNANCY DIABETES MELLITUS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; TISSUE INJURY;

EID: 84901038216     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00023     Document Type: Article

References (91)

1. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev (2006) 86:747-803. doi:10.1152/physrev.00036.2005.
2. Ellis B, Li XC, Miguel-Qin E, Gu V, Zhuo JL. Evidence for a functional intracellular angiotensin system in the proximal tubule of the kidney. Am J Physiol Regul Integr Comp Physiol (2012) 302:R494-509. doi:10.1152/ajpregu.00487.2011.
3. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev (2007) 59:251-87. doi:10.1124/pr.59.3.3.
4. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol (2002) 89:3A-9A. doi:10.1016/S0002-9149(01)02321-9.
5. Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia (2012) 55:566-78. doi:10.1007/s00125-011-2398-8.
6. Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol (2012) 302:H1219-30. doi:10.1152/ajpheart.00796.2011.
7. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab (2004) 30:487-96. doi:10.1016/S1262-3636(07)70146-5.
8. McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 362:1477-90. doi:10.1056/NEJMoa1001121.
9. Singh R, Singh AK, Alavi N, Leehey DJ. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol (2003) 14:873-80. doi:10.1097/01.ASN.0000060804.40201.6E.
10. Singh VP, Le B, Bhat VB, Baker KM, Kumar R. High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol (2007) 293:H939-48. doi:10.1152/ajpheart.00391.2007.
11. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes (2008) 57:3297-306. doi:10.2337/db08-0805.
12. Mima A, Hiraoka-Yamomoto J, Li Q, Kitada M, Li C, Geraldes P, et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes. Diabetes (2012) 61:2967-79. doi:10.2337/db11-1824.
13. Zhang SL, Tang SS, Chen X, Filep JG, Ingelfinger JR, Chan JSD. High levels of glucose stimulate angiotensinogen gene expression via the P38 mitogen-activated protein kinase pathway in rat kidney proximal tubular cells. Endocrinology (2000) 141:4637-46. doi:10.1210/endo.141.12.7844.
14. Zhang SL, Filep JG, Hohman TC, Tang SS, Ingelfinger JR, Chan JSD. Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int (1999) 55:454-64. doi:10.1046/j.1523-1755.1999.00271.x.
15. Peti-Peterdi J. High glucose and renin release: the role of succinate and GPR91. Kidney Int (2010) 78:1214-7. doi:10.1038/ki.2010.333.
16. van der Zijl NJ, Moors CC, Goossens GH, Hermans MM, Blaak EE, Diamant M. Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Diabetes Care (2011) 34:845-51. doi:10.2337/dc10-2224.
17. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 355:1551-62. doi:10.1056/NEJMoa065061.
18. Goossens GH. The renin-angiotensin system in the pathophysiology of type 2 diabetes. Obes Facts (2012) 5:611-24. doi:10.1159/000342776.
19. Henriksen EJ. Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol (2007) 293:R974-80. doi:10.1152/ajpregu.00147.2007.
20. Wang HW, Mizuta M, Saitoh Y, Noma K, Ueno H, Nakazato M. Glucagon-like peptide-1 and candesartan additively improve glucolipotoxicity in pancreatic beta-cells. Metabolism (2011) 60:1081-9. doi:10.1016/j.metabol.2010.11.004.
21. Kalupahana NS, Moustaid-Moussa N. The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. Obes Rev (2012) 13:136-49. doi:10.1111/j.1467-789X.2011.00942.x.
22. Lu H, Boustany-Kari CM, Daugherty A, Cassis LA. Angiotensin II increases adipose angiotensinogen expression. Am J Physiol Endocrinol Metab (2007) 292:E1280-7. doi:10.1152/ajpendo.00277.2006.
23. Giacchetti G, Faloia E, Mariniello B, Sardu C, Gatti C, Camilloni MA, et al. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens (2002) 15:381-8. doi:10.1016/S0895-7061(02)02257-4.
24. Bastien M, Poirier P, Lemieux I, Després JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis (2014) 56:369-81. doi:10.1016/j.pcad.2013.10.016.
25. Miesel A, Muller-Fielitz H, Johren O, Vogt FM, Raasch W. Double blockade of angiotensin II (AT(1))-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats. Br J Pharmacol (2012) 165:2721-35. doi:10.1111/j.1476-5381.2011.01726.x.
26. Fogari R, Derosa G, Zoppi A, Rinaldi A, Lazzari P, Fogari E, et al. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res (2005) 28:209-14. doi:10.1291/hypres.28.209.
27. Cassis L, Helton M, English V, Burke G. Angiotensin II regulates oxygen consumption. Am J Physiol Regul Integr Comp Physiol (2002) 282:R445-53. doi:10.1152/ajpregu.00261.2001.
28. Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J (2001) 15:2727-9. doi:10.1096/fj.01-0457fje.
29. Baker KM, Chernin MI, Wixson SK, Aceto JF. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol (1990) 259:H324-32.
30. Becker BN, Yasuda T, Kondo S, Vaikunth S, Homma T, Harris RC. Mechanical stretch/relaxation stimulates a cellular renin-angiotensin system in cultured rat mesangial cells. Exp Nephrol (1998) 6:57-66. doi:10.1159/000020505.
31. Johnston AP, Baker J, De Lisio M, Parise G. Skeletal muscle myoblasts possess a stretch-responsive local angiotensin signalling system. J Renin Angiotensin Aldosterone Syst (2011) 12:75-84. doi:10.1177/1470320310381795.
32. Skov J, Dejgaard A, Frokiaer J, Holst JJ, Jonassen T, Rittig S, et al. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab (2013) 98:E664-71. doi:10.1210/jc.2012-3855.
33. Hirata K, Kume S, Araki S, Sakaguchi M, Chin-Kanasaki M, Isshiki K, et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun (2009) 380:44-9. doi:10.1016/j.bbrc.2009.01.003.
34. Ishibashi Y, Matsui T, Ojima A, Nishino Y, Nakashima S, Maeda S, et al. Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. Microvasc Res (2012) 84:395-8. doi:10.1016/j.mvr.2012.06.008.
35. Cheng Q, Law PK, de Gasparo M, Leung PS. Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-l-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes. J Pharmacol Exp Ther (2008) 327:683-91. doi:10.1124/jpet.108.142703.
36. Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsboll T. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab (2011) 96:737-45. doi:10.1210/jc.2010-2435.
37. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab (2001) 86:3717-23. doi:10.1210/jcem.86.8.7743.
38. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes (2003) 52:380-6. doi:10.2337/diabetes.52.2.380.
39. Rodriguez R, Viscarra JA, Minas JN, Nakano D, Nishiyama A, Ortiz RM. Angiotensin receptor blockade increases pancreatic insulin secretion and decreases glucose intolerance during glucose supplementation in a model of metabolic syndrome. Endocrinology (2012) 153:1684-95. doi:10.1210/en.2011-1885.
40. Aubert J, Darimont C, Safonova I, Ailhaud G, Negrel R. Regulation by glucocorticoids of angiotensinogen gene expression and secretion in adipose cells. Biochem J (1997) 328(Pt 2):701-6.
41. Wang L, Lei C, Zhang SL, Roberts KD, Tang SS, Ingelfinger JR, et al. Synergistic effect of dexamethasone and isoproterenol on the expression of angiotensinogen in immortalized rat proximal tubular cells. Kidney Int (1998) 53:287-95. doi:10.1046/j.1523-1755.1998.00759.x.
42. Zhang SL, Chen X, Wei CC, Filep JG, Tang SS, Ingelfinger JR, et al. Insulin inhibits dexamethasone effect on angiotensinogen gene expression and induction of hypertrophy in rat kidney proximal tubular cells in high glucose. Endocrinology (2002) 143:4627-35. doi:10.1210/en.2002-220408.
43. Dostal DE, Booz GW, Baker KM. Regulation of angiotensinogen gene expression and protein in neonatal rat cardiac fibroblasts by glucocorticoid and beta-adrenergic stimulation. Basic Res Cardiol (2000) 95:485-90. doi:10.1007/s003950070025.
44. Sato A, Suzuki H, Murakami M, Nakazato Y, Iwaita Y, Saruta T. Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension (1994) 23:25-30.
45. Sato A, Suzuki H, Nakazato Y, Shibata H, Inagami T, Saruta T. Increased expression of vascular angiotensin II type 1A receptor gene in glucocorticoid-induced hypertension. J Hypertens (1994) 12:511-6.
46. Breidert M, Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA, Holst JJ. Angiotensin II regulates both adrenocortical and adrenomedullary function in isolated perfused pig adrenals. Peptides (1996) 17:287-92. doi:10.1016/0196-9781(95)02106-X.
47. Romero DG, Welsh BL, Gomez-Sanchez EP, Yanes LL, Rilli S, Gomez-Sanchez CE. Angiotensin II-mediated protein kinase D activation stimulates aldosterone and cortisol secretion in H295R human adrenocortical cells. Endocrinology (2006) 147:6046-55. doi:10.1210/en.2006-0794.
48. Chiu KC, Chu A, Go VLW, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr (2004) 79:820-5.
49. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 376:1543-51. doi:10.1016/S0140-6736(10)61032-X.
50. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, et al. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chim Acta (2010) 411:1354-60. doi:10.1016/j.cca.2010.05.037.
51. Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension (2010) 55:1283-8. doi:10.1161/HYPERTENSIONAHA.109.148619.
52. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest (2002) 110:229-38. doi:10.1172/JCI15219.
53. Cheng Q, Li YC, Boucher BJ, Leung PS. A novel role for vitamin D: modulation of expression and function of the local renin-angiotensin system in mouse pancreatic islets. Diabetologia (2011) 54:2077-81. doi:10.1007/s00125-011-2100-1.
54. Li YC. Chapter 40-vitamin d and the renin-angiotensin system. Third ed. In: David F, Pike JW, Adams JohnS, Feldman David, John SA editors. Vitamin D. San Diego: Academic Press (2011). p. 707-23. doi:10.1016/B978-0-12-381978-9.10040-X.
55. Vaidya A, Williams JS. The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes. Metabolism (2012) 61:450-8. doi:10.1016/j.metabol.2011.09.007.
56. Ferder M, Inserra F, Manucha W, Ferder L. The world pandemic of vitamin D deficiency could possibly be explained by cellular inflammatory response activity induced by the renin-angiotensin system. Am J Physiol Cell Physiol (2013) 304:C1027-39. doi:10.1152/ajpcell.00403.2011.
57. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care (1997) 20:537-44. doi:10.2337/diacare.20.4.537.
58. Agarwal D, Welsch MA, Keller JN, Francis J. Chronic exercise modulates RAS components and improves balance between pro-and anti-inflammatory cytokines in the brain of SHR. Basic Res Cardiol (2011) 106:1069-85. doi:10.1007/s00395-011-0231-7.
59. Barretti DL, Magalhaes Fde C, Fernandes T, do Carmo EC, Rosa KT, Irigoyen MC, et al. Effects of aerobic exercise training on cardiac renin-angiotensin system in an obese zucker rat strain. PLoS One (2012) 7:e46114. doi:10.1371/journal.pone.0046114.
60. Pereira MG, Ferreira JC, Bueno CR Jr, Mattos KC, Rosa KT, Irigoyen MC, et al. Exercise training reduces cardiac angiotensin II levels and prevents cardiac dysfunction in a genetic model of sympathetic hyperactivity-induced heart failure in mice. Eur J Appl Physiol (2009) 105:843-50. doi:10.1007/s00421-008-0967-4.
61. Ciampone S, Borges R, de Lima IP, Mesquita FF, Cambiucci EC, Gontijo JA. Long-term exercise attenuates blood pressure responsiveness and modulates kidney angiotensin II signalling and urinary sodium excretion in SHR. J Renin Angiotensin Aldosterone Syst (2011) 12:394-403. doi:10.1177/1470320311408750.
62. Maeda S, Iemitsu M, Jesmin S, Miyauchi T. Acute exercise causes an enhancement of tissue renin-angiotensin system in the kidney in rats. Acta Physiol Scand (2005) 185:79-86. doi:10.1111/j.1365-201X.2005.01459.x.
63. Mueller PJ. Exercise training and sympathetic nervous system activity: evidence for physical activity dependent neural plasticity. Clin Exp Pharmacol Physiol (2007) 34:377-84. doi:10.1111/j.1440-1681.2007.04590.x.
64. Schrier RW. Interactions between angiotensin II and arginine vasopressin in water homeostasis. Kidney Int (0000) 76:137-9. doi:10.1038/ki.2009.103.
65. Yang S, Yao B, Zhou Y, Yin H, Zhang MZ, Harris RC. Intrarenal dopamine modulates progressive angiotensin II-mediated renal injury. Am J Physiol Renal Physiol (2012) 302:F742-9. doi:10.1152/ajprenal.00583.2011.
66. Zhang MZ, Yao B, Fang X, Wang S, Smith JP, Harris RC. Intrarenal dopaminergic system regulates renin expression. Hypertension (2009) 53:564-70. doi:10.1161/HYPERTENSIONAHA.108.127035.
67. Li H, Armando I, Yu P, Escano C, Mueller SC, Asico L, et al. Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. J Clin Invest (2008) 118:2180-9. doi:10.1172/JCI33637.
68. Cheng HF, Becker BN, Harris RC. Dopamine decreases expression of type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest (1996) 97:2745-52. doi:10.1172/JCI118729.
69. de Kloet AD, Krause EG, Woods SC. The renin angiotensin system and the metabolic syndrome. Physiol Behav (2010) 100:525-34. doi:10.1016/j.physbeh.2010.03.018.
70. Irani RA, Xia Y. The functional role of the renin-angiotensin system in pregnancy and preeclampsia. Placenta (2008) 29:763-71. doi:10.1016/j.placenta.2008.06.011.
71. Shao W, Seth DM, Navar LG. Augmentation of endogenous intrarenal angiotensin II levels in Val5-ANG II-infused rats. Am J Physiol Renal Physiol (2009) 296:F1067-71. doi:10.1152/ajprenal.90596.2008.
72. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol (2007) 292:C82-97. doi:10.1152/ajpcell.00287.2006.
73. Zhang GX, Lu XM, Kimura S, Nishiyama A. Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation. Cardiovasc Res (2007) 76:204-12. doi:10.1016/j.cardiores.2007.07.014.
74. Erdmann B, Fuxe K, Ganten D. Subcellular localization of angiotensin II immunoreactivity in the rat cerebellar cortex. Hypertension (1996) 28:818-24. doi:10.1161/01.HYP.28.5.818.
75. Wilkinson-Berka JL, Agrotis A, Deliyanti D. The retinal renin-angiotensin system: roles of angiotensin II and aldosterone. Peptides (2012) 36:142-50. doi:10.1016/j.peptides.2012.04.008.
76. Kasselman LJ, Rutkove SB. Application of angiotensin II to healthy rat sciatic nerve can produce neuropathy without associated vasculopathy. Muscle Nerve (2010) 42:959-65. doi:10.1002/mus.21767.
77. Jin LM. Angiotensin II signaling and its implication in erectile dysfunction. J Sex Med (2009) 3(6 Suppl):302-10. doi:10.1111/j.1743-6109.2008.01188.x.
78. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature (2001) 414:813-20. doi:10.1038/414813a.
79. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol (2007) 166:495-505. doi:10.1093/aje/kwm106.
80. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int (2007) 18:427-44. doi:10.1007/s00198-006-0253-4.
81. Gebru Y, Diao TY, Pan H, Mukwaya E, Zhang Y. Potential of RAS inhibition to improve metabolic bone disorders. Biomed Res Int (2013) 2013:932691. doi:10.1155/2013/932691.
82. Donmez BO, Ozdemir S, Sarikanat M, Yaras N, Koc P, Demir N, et al. Effect of angiotensin II type 1 receptor blocker on osteoporotic rat femurs. Pharmacol Rep (2012) 64:878-88.
83. Solomon DH, Mogun H, Garneau K, Fischer MA. Risk of fractures in older adults using antihypertensive medications. J Bone Miner Res (2011) 26:1561-7. doi:10.1002/jbmr.356.
84. Nuche-Berenguer B, Moreno P, Portal-Nunez S, Dapia S, Esbrit P, Villanueva-Penacarrillo ML. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept (2010) 159:61-6. doi:10.1016/j.regpep.2009.06.010.
85. Nuche-Berenguer B, Moreno P, Esbrit P, Dapia S, Caeiro JR, Cancelas J, et al. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int (2009) 84:453-61. doi:10.1007/s00223-009-9220-3.
86. Nishimura H. Angiotensin receptors-evolutionary overview and perspectives. Comp Biochem Physiol A Mol Integr Physiol (2001) 128:11-30. doi:10.1016/S1095-6433(00)00294-4.
87. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther (2008) 120:292-316. doi:10.1016/j.pharmthera.2008.08.009.
88. Kumar R, Thomas CM, Yong QC, Chen W, Baker KM. The intracrine renin-angiotensin system. Clin Sci (1979) 123(2012):273-84. doi:10.1042/CS20120089.
89. Kobori H, Navar LG. Urinary angiotensinogen as a novel biomarker of intrarenal renin-angiotensin system in chronic kidney disease. Int Rev Thromb (2011) 6:108-16.
90. Persson F, Lu X, Rossing P, Garrelds IM, Danser AH, Parving HH. Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin? J Hypertens (2013) 31:1646-52. doi:10.1097/HJH.0b013e328362217c.
91. Astin R, Bentham R, Djafarzadeh S, Horscroft JA, Kuc RE, Leung PS, et al. No evidence for a local renin-angiotensin system in liver mitochondria. Sci Rep (2013) 3:2467. doi:10.1038/srep02467.